Lymph node classification in E‑PSMA reporting guidelines for PSMA‑PET

Daniela E. Oprea-Lager; Francesco Ceci; Matthias Eiber; Stefano Fanti; Ken Herrmann

doi:10.1007/s00259-022-06007-0

Lymph node classification in E‑PSMA reporting guidelines for PSMA‑PET

Daniela E. Oprea-Lager^*
, Francesco Ceci
, Matthias Eiber
, Stefano Fanti
, Ken Herrmann

^*Corresponding author for this work

Amsterdam UMC
IRCCS Istituto Europeo di Oncologia - Milano
University of Milan
Technical University of Munich
IRCCS S. Orsola University Hospital, Bologna, Italy
University of Duisburg-Essen
International Centre for Rural Health of the San Paolo Hospital
Alma Mater University, Bologna, Italy

Research output: Contribution to journal › Comment/Letter to the editor › Academic

23 Downloads (Pure)

Original language	English
Pages (from-to)	10-11
Number of pages	2
Journal	European journal of nuclear medicine and molecular imaging
Volume	50
Issue number	1
Early online date	2022
DOIs	https://doi.org/10.1007/s00259-022-06007-0
Publication status	Published - 1 Dec 2022

Access to Document

10.1007/s00259-022-06007-0

Lymph-node-classification-in-epsma-reporting-guidelines-for-psmapet.pdfFinal published version, 475 KBLicence: Taverne

Cite this

@article{2bb810c63ef3489d8938c4859847a06a,

title = "Lymph node classification in E‑PSMA reporting guidelines for PSMA‑PET",

author = "Oprea-Lager, \{Daniela E.\} and Francesco Ceci and Matthias Eiber and Stefano Fanti and Ken Herrmann",

note = "Funding Information: Daniela E. Oprea-Lager reports unrestricted grants from Janssen for Consensus meetings attendance, outside the submitted work. Francesco Ceci declares no competing interests in relation with the submitted work. Matthias Eiber reports prior consulting activities for BED, Novartis, Telix, Progenics, Bayer, Point Biopharma, and Janssen and a patent application for rhPSMA, all outside the submitted work. Stefano Fanti reports personal fees from ANMI, Astellas, Bayer, Blue Earth Diagnostics, GE Healthcare, Janssen, Novartis, and Sofie Biosciences, and nonfinancial support from Advanced Accelerator Applications (AAA), Bayer, GE Health- care, Curium, Tema Sinergie, Sanofi, and Telix, outside the submitted work. Ken Herrmann reports personal fees from Bayer, SIR- TEX, Adacap, Curium, Endocyte, BTG, Ipsen, Siemens Healthineers, GE Healthcare, Amgen, Novartis, and Y-mAbs; stock options in Sofie Bio-sciences; nonfinancial support from ABX; and grants from BTG, outside the submitted work.",

year = "2022",

month = dec,

day = "1",

doi = "10.1007/s00259-022-06007-0",

language = "English",

volume = "50",

pages = "10--11",

journal = "European journal of nuclear medicine and molecular imaging",

issn = "1619-7070",

publisher = "Springer Verlag",

number = "1",

}

TY - JOUR

T1 - Lymph node classification in E‑PSMA reporting guidelines for PSMA‑PET

AU - Oprea-Lager, Daniela E.

AU - Ceci, Francesco

AU - Eiber, Matthias

AU - Fanti, Stefano

AU - Herrmann, Ken

N1 - Funding Information: Daniela E. Oprea-Lager reports unrestricted grants from Janssen for Consensus meetings attendance, outside the submitted work. Francesco Ceci declares no competing interests in relation with the submitted work. Matthias Eiber reports prior consulting activities for BED, Novartis, Telix, Progenics, Bayer, Point Biopharma, and Janssen and a patent application for rhPSMA, all outside the submitted work. Stefano Fanti reports personal fees from ANMI, Astellas, Bayer, Blue Earth Diagnostics, GE Healthcare, Janssen, Novartis, and Sofie Biosciences, and nonfinancial support from Advanced Accelerator Applications (AAA), Bayer, GE Health- care, Curium, Tema Sinergie, Sanofi, and Telix, outside the submitted work. Ken Herrmann reports personal fees from Bayer, SIR- TEX, Adacap, Curium, Endocyte, BTG, Ipsen, Siemens Healthineers, GE Healthcare, Amgen, Novartis, and Y-mAbs; stock options in Sofie Bio-sciences; nonfinancial support from ABX; and grants from BTG, outside the submitted work.

PY - 2022/12/1

Y1 - 2022/12/1

UR - https://www.scopus.com/pages/publications/85140088957

UR - https://www.ncbi.nlm.nih.gov/pubmed/36241913

UR - https://www.scopus.com/pages/publications/85140088957

U2 - 10.1007/s00259-022-06007-0

DO - 10.1007/s00259-022-06007-0

M3 - Comment/Letter to the editor

C2 - 36241913

SN - 1619-7070

VL - 50

SP - 10

EP - 11

JO - European journal of nuclear medicine and molecular imaging

JF - European journal of nuclear medicine and molecular imaging

IS - 1

ER -

Lymph node classification in E‑PSMA reporting guidelines for PSMA‑PET

Access to Document

Other files and links

Cite this